Select Conferences

ReachBio Partners with Axiogenesis to Distribute Cell-Based Products in North America

Date Posted: Tuesday, February 26, 2008

Print Email to a friend

ReachBio LLC has announced that it will distribute the full product line of Axiogenesis AG to the North American life science research and drug discovery market.

Axiogenesis’ products consist of highly pure and well-characterized tissue-specific cells derived from specially engineered mouse embryonic stem cell lines. Major applications for the cells include drug discovery, toxicity testing of new drug candidates and other compounds, and basic research.

The first cell types available from Axiogenesis are 99.9% pure atrial cardiomyocytes in various formats, including frozen cryovials, pre-seeded 96-well plates, and pre-seeded coverslips.

Branded as Cor.AT cells, these cardiomyocytes have been rigorously functionally qualified and found to be ideal for cardiotoxicity screening, electrophysiology studies, and as a cellular model system for hypertrophic cardiomyopathy. Pure ventricular cardiomyocytes (Cor.VE) are also available.

Further Information: